These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 19586325)

  • 1. Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis.
    Duh MS; Dial E; Choueiri TK; Fournier AA; Antras L; Rodermund D; Neary MP; Oh WK
    Curr Med Res Opin; 2009 Aug; 25(8):2081-90. PubMed ID: 19586325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review.
    Choueiri TK; Duh MS; Clement J; Brick AJ; Rogers MJ; Kwabi C; Shah K; Percy AG; Antràs L; Jayawant SS; Chen K; Wang ST; Luka A; Neary MP; McDermott D; Oh WK
    BJU Int; 2010 May; 105(9):1247-54. PubMed ID: 19863525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: results from a medical chart review study.
    Choueiri TK; McDermott D; Sheng Duh M; Sarda SP; Neary MP; Oh WK
    Urol Oncol; 2012; 30(6):848-55. PubMed ID: 20926319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
    Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
    Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic burden of adverse events in patients with metastatic renal cell carcinoma.
    Hagiwara M; Borker R; Oster G
    Clin Ther; 2013 Dec; 35(12):1955-1963.e2. PubMed ID: 24290735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of metastatic renal cell carcinoma.
    Reeves DJ; Liu CY
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
    Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Staehler M; Negrier S; Chevreau C; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Anderson S; Hofilena G; Shan M; Pena C; Lathia C; Bukowski RM
    J Clin Oncol; 2009 Jul; 27(20):3312-8. PubMed ID: 19451442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the economic burden of breast cancer in a US managed care population.
    Barron JJ; Quimbo R; Nikam PT; Amonkar MM
    Breast Cancer Res Treat; 2008 May; 109(2):367-77. PubMed ID: 17674201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer.
    Yang H; Yu AP; Wu EQ; Yim YM; Yu E
    J Med Econ; 2011; 14(5):542-52. PubMed ID: 21728912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination targeted therapy in advanced renal cell carcinoma.
    Sosman J; Puzanov I
    Cancer; 2009 May; 115(10 Suppl):2368-75. PubMed ID: 19402058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma.
    Hagiwara M; Hackshaw MD; Oster G
    J Med Econ; 2013 Nov; 16(11):1300-6. PubMed ID: 24004437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The economic effect of oral linezolid versus intravenous vancomycin in the outpatient setting: the payer perspective.
    McKinnon PS; Carter CT; Girase PG; Liu LZ; Carmeli Y
    Manag Care Interface; 2007 Jan; 20(1):23-34. PubMed ID: 17310650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EORTC-GU group expert opinion on metastatic renal cell cancer.
    de Reijke TM; Bellmunt J; van Poppel H; Marreaud S; Aapro M
    Eur J Cancer; 2009 Mar; 45(5):765-73. PubMed ID: 19157861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimation of economic costs associated with transfusion dependence in adults with MDS.
    Frytak JR; Henk HJ; De Castro CM; Halpern R; Nelson M
    Curr Med Res Opin; 2009 Aug; 25(8):1941-51. PubMed ID: 19552620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer.
    Bukowski R; Cella D; Gondek K; Escudier B;
    Am J Clin Oncol; 2007 Jun; 30(3):220-7. PubMed ID: 17551296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New treatment approaches in renal cell carcinoma.
    Facchini G; Perri F; Caraglia M; Pisano C; Striano S; Marra L; Fiore F; Aprea P; Pignata S; Iaffaioli RV
    Anticancer Drugs; 2009 Nov; 20(10):893-900. PubMed ID: 19752718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study.
    Faught RE; Weiner JR; Guérin A; Cunnington MC; Duh MS
    Epilepsia; 2009 Mar; 50(3):501-9. PubMed ID: 19183224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of comorbid depression or anxiety on patterns of treatment and economic outcomes among patients with diabetic peripheral neuropathic pain.
    Boulanger L; Zhao Y; Foster TS; Fraser K; Bledsoe SL; Russell MW
    Curr Med Res Opin; 2009 Jul; 25(7):1763-73. PubMed ID: 19505204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population.
    Kruse GB; Amonkar MM; Smith G; Skonieczny DC; Stavrakas S
    J Manag Care Pharm; 2008; 14(9):844-57. PubMed ID: 19006441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postdischarge oral versus injectable anticoagulation following major orthopedic surgery.
    Shorr AF; Nutescu EA; Farrelly E; Horblyuk R; Happe LE; Franklin M
    Ann Pharmacother; 2008 Sep; 42(9):1222-8. PubMed ID: 18664606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.